NCT00695305 - An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions

Atherosclerosis

Interventions

DRUG

rilapladib

250 mg oral dose once daily

DRUG

placebo

OTHER

18F Fluorodeoxylucose (FDG)-PET

FDG-PET

Trial Locations (10)

GSK Investigational Site, New York

GSK Investigational Site, New York

GSK Investigational Site, New York

GSK Investigational Site, New York

GSK Investigational Site, North Massapequa

GSK Investigational Site, Boston

GSK Investigational Site, Brockton

GSK Investigational Site, Haverhill

GSK Investigational Site, Linden

GSK Investigational Site, Warwick